Eledon's Tegoprubart Achieves 100% Insulin Independence in Type 1 Diabetes Islet Transplant Trial
Event summary
- 12-patient cohort fully enrolled with an average time since transplant of approximately 8 months
- 100% insulin independence achieved in 10 patients over 4 weeks post-transplant
- No signs of graft rejection or de novo donor-specific HLA antibodies observed
- Tegoprubart demonstrated a favorable safety and tolerability profile
- Data presented at the ATTD conference in Barcelona, Spain on March 11-14, 2026
The big picture
Eledon's positive trial results position tegoprubart as a potential game-changer in islet transplantation for type 1 diabetes, offering a safer alternative to traditional immunosuppression regimens. The data supports broader applications in organ transplantation and autoimmune diseases, aligning with industry trends toward targeted immunotherapies. With Breakthrough T1D's funding commitment, Eledon is well-positioned to advance its clinical program and potentially capture a significant share of the transplant immunosuppression market.
What we're watching
- Regulatory Pathway
- Whether Eledon can secure FDA guidance on tegoprubart's path to market for islet cell transplantation later this year.
- Clinical Validation
- The pace at which additional data will confirm tegoprubart's efficacy and safety in larger, more diverse patient populations.
- Competitive Positioning
- How Eledon's calcineurin inhibitor-free regimen will differentiate it in the transplant immunosuppression market.
Related topics